Hugo F. Fernandez, M vigora .D., Zhuoxin Sun, Ph.D., Xiaopan Yao, Ph.D., Mark R. Litzow, M.D., Selina M. Luger, M.D., Elisabeth M. Paietta, Ph.D., Janis Racevskis, Ph.D., Gordon W. Dewald, Ph.D., Rhett P. Ketterling, M.D., John M. Bennett, M.D., Jacob M. Rowe, M.D., Hillard M. Lazarus, M.D., and Martin S. Tallman, M.D.: Anthracycline Dose Intensification in Acute Myeloid Leukemia The survival of sufferers with acute myeloid leukemia is suffering from many variables, including therapy that induces complete remission and appropriate consolidation therapy. Currently, anthracycline plus cytarabine is the normal induction therapy for patients with AML.1 The trusted intravenous mix of daunorubicin , given daily for 3 times, and cytarabine , given daily for 7 days, results in complete remission in 50 to 75 percent of patients.1,2 Neither the addition of other medicines to daunorubicin and cytarabine3 nor intensification of the dosage of cytarabine4-6 has been proven to improve the outcome.
In this article, we measure the reported case group of severe pneumonia and compare this patterns regarding morbidity and mortality with patterns from latest influenza epidemics in Mexico. Crucial epidemiologic factors, like the age pattern of morbidity and mortality during the 2009 epidemic, are inferred due to the limited availability of diagnostic checks and data. Given the relatively quick global spread of the newly described pathogen,8 early identification of groups at risk for serious pneumonia can certainly help in prioritizing the use of vaccines and antiviral drugs when confronted with limited supplies.